Lifevantage Corporation Common Stock (Delaware) (LFVN)
Slow GrowerFairStock Score: 59/100 — STEADY
Key Financials
| Current Price | $5.17 |
| Market Cap | $62M |
| P/E Ratio | 11.49 |
| ROE | 17.08% |
| Dividend Yield | 2% |
| Sector | Consumer Defensive |
Strengths
- High return on equity of 25.0% demonstrating efficient capital deployment
- Conservative balance sheet with debt-to-equity of just 0.32, providing financial flexibility
- Attractive 3.7% dividend yield providing steady income returns
Concerns
- Revenue declining at 27.8% year-over-year signals potential demand weakness or market share loss
- Altman Z-Score of 0.2 places it in the financial distress zone—elevated bankruptcy risk
AI Analysis
Lifevantage Corporation Common Stock (Delaware) is a micro-cap consumer defensive company valued at $62 million. The business generates $210 million in annual revenue with a 0.1% net margin. From a quality standpoint, Lifevantage shows distressed Altman Z-Score of 0.2 warrants caution and strong 25% ROE. On valuation, the stock is deeply undervalued on a P/E basis at 8.3x, with a modest 18% margin of safety vs Graham Number. Growth dynamics show revenue growing at -27.8% and profit growth of -89.2%. The 3.7% dividend yield adds an income component for patient holders. Our composite FairStock Score of 59/100 reflects mixed fundamentals overall. This combination of reasonable valuation, solid returns, and conservative leverage makes it worth a closer look for value-oriented portfolios.
Bull Case
The market underappreciates Lifevantage's consistent 25% ROE at just 8x earnings—a re-rating toward sector peers could unlock 30-50% upside. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.
Bear Case
Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the consumer defensive space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.
Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer